Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Michael J Reardon Added: 11 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more
Author(s): Marat Fudim , David Duncker Added: 4 weeks ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19… View more
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 5 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more
Author(s): Christina Magnussen Added: 11 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more
Author(s): Danxia Yu Added: 11 months ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,… View more
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more
Author(s): Paul M Ridker Added: 2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more
Author(s): Martin B Leon Added: 2 years ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more
Author(s): Safia Chatur Added: 9 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more
Author(s): Carl Streed Added: 2 years ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental… View more